Dexamethasone, rituximab and cyclophosphamide for relapsed and/or refractory and treatment‐naïve patients with Waldenstrom macroglobulinemia
Sign Up to like & getrecommendations! Published in 2017 at "British Journal of Haematology"
DOI: 10.1111/bjh.14826
Abstract: The management of Waldenström macroglobulinaemia (WM) relies predominantly on small trials, one of which has demonstrated activity of dexamethasone, rituximab and cyclophosphamide (DRC) in the frontline setting. We report on the efficacy of DRC, focusing… read more here.
Keywords: relapsed refractory; rituximab cyclophosphamide; dexamethasone rituximab;
Rituximab and Cyclophosphamide Based Regimens for Treatment of Waldensterom Macroglobulemia, Lessons from Clinical Literature: A Systemic Review
Sign Up to like & getrecommendations! Published in 2020 at "Blood"
DOI: 10.1182/blood-2020-138964
Abstract: Introduction: Waldenström's macroglobulinemia is a rare low-grade lymphoplasmacytic lymphoma characterized by CD20 expression on malignant cells and produces a monoclonal immunoglobulin M (IgM). Rituximab is a chimeric monoclonal antibody against CD20 antigen and the most… read more here.
Keywords: response rate; rituximab cyclophosphamide; major response; response ... See more keywords